Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Nurix Therapeutics, Inc. (NRIX) reported a quarterly loss of $0.67 per share, better than the Zacks Consensus Estimate of a loss of$0.72, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of 6.94$18.45 million for the quarter ended February 2025, exceeding the Zacks Consensus Estimate by 26.41%, compared to $16.59 million in the same quarter last year [2] - Nurix Therapeutics shares have declined approximately 48.4$0.74 on revenues of $14.87 million, and for the current fiscal year, it is -$3.06 on revenues of $61.09 million [7] - The estimate revisions trend for Nurix Therapeutics is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Nurix Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]